The classification of steatotic liver disease is being reconsidered as a dynamic and interconnected process, according to an article published in eGastroenterology by Dr. Chen, Dr. Horn, and Prof. Tacke from Charité - Universitätsmedizin Berlin on June 30. The authors say that metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease should not be seen as rigid diagnostic categories but as evolving trajectories.
The current framework was developed to reflect the biological overlap between metabolic dysfunction and alcohol exposure. However, the authors say existing classifications rely on single-point assessments of alcohol intake and metabolic status, while these exposures can change significantly over time. They present cohort data showing substantial migration across subclasses within six months: 36% of individuals initially classified as having both metabolic dysfunction and alcohol association shifted to other subtypes, while 32% with alcohol-associated liver disease transitioned to other categories.
The article describes how both alcohol exposure and metabolic dysfunction converge on shared pathways such as lipotoxicity, oxidative stress, inflammation, and fibrosis progression. Alcohol consumption can worsen obesity-related conditions like hypertriglyceridemia or hypertension; conversely, underlying metabolic issues may heighten vulnerability to alcohol-induced injury.
Accurate assessment of alcohol intake remains a challenge in clinical practice due to underreporting—self-reported consumption may underestimate true levels by up to 57.7%. The study highlights the use of objective biomarkers such as phosphatidylethanol (PEth), which reflects recent drinking more reliably than questionnaires.
Looking forward, the authors propose integrating longitudinal reassessment into patient management by tracking changes in exposures alongside non-invasive fibrosis risk stratification tools like FIB-4 or vibration-controlled transient elastography. This approach could also impact clinical trial design for new therapies by requiring repeated monitoring throughout studies rather than relying solely on initial diagnostic labels.
